Lv1
15 积分 2020-08-25 加入
P3.08F.01 Interim Analysis of a Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)
21小时前
求助中
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance
17天前
已完结
Comparative Efficacy and Safety of Lorlatinib vs. Alectinib and Lorlatinib vs. Brigatinib for ALK-positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
1个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
1个月前
已完结
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
1个月前
已关闭
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
2个月前
已完结
Randomized Trial of Surgery Versus Radiotherapy in Patients with Stage IIIA (N2) Non–Small-Cell Lung Cancer After a Response to Induction Chemotherapy: EORTC 08941
2个月前
已完结
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
2个月前
已完结
Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer
2个月前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
2个月前
已完结
皖公网安备34019202002308
